Through this Partnership, additional Go-To-Market Partners will go live and the Adoption of GENEVA OS™ will Rapidly Expand
PALO ALTO, CA – June 17, 2024 – Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a strategic partnership with Norstella, one of the largest global pharma intelligence solution providers. This collaboration follows Atropos Health’s recent announcement of $33 million in Series B funding, furthering its expansion into life sciences. Through this partnership, Atropos Health will leverage Norstella’s extensive reach, including companies such as Panalgo, Citeline, Evaluate, MMIT, and The Dedham Group, to rapidly expand the adoption of its Generative AI platform, GENEVA OS™. In the first of a series of planned initiatives, Panalgo Instant Health Data (IHD) customers will gain access to Atropos Health’s comprehensive suite of evidence-generation tools and Atropos Health users will soon see enhanced capability as Citeline’s leading clinical trial intelligence solution, Trialtrove, is integrated into Atropos Health’s CRAFT (Clinical Research Acceleration for Trials) Emulation Toolkit™.
Read the full press release to learn more.